Do you know that a TB vaccine called Bacillus Calmette-Guerin (BCG) can be effective in fighting coronavirus? Yes, you read it right. This is what a new researched appeared in the pre-print repository medRxiv, states. According to the study, national differences in impact of coronavirus could be partially explained by the different national policies respect to BCG childhood vaccination. Also Read - Indian Businessman Donates Entire Building For Coronavirus Quarantine in Dubai
The BCG vaccine is being used from a long time worldwide. Apart from preventing the the onset of TB, the vaccine provides protection against meningitis and respiratory infections too. Also Read - COVID-19: Neymar Denies Flouting Social Distancing Protocols Amid Coronavirus
To know the role of this vaccine in treating coronavirus, researchers recently conducted a study during which scientists compared large number of countries BCG vaccination policies with the morbidity and mortality for COVID-19. Also Read - COVID-19: Poonam Yadav Donates Rs 2 Lakh to Aid in The Fight Against Coronavirus Pandemic
The study results showed that countries like Italy and the Netherlands, that do not have universal policies of BCG vaccination have been more severely affected compared to countries with universal and long-standing BCG policies.
The research also showed that countries that have a late start of universal BCG policy, for example, Iran, where universal BCG vaccination policy started in 1984, had high mortality, consistent with the idea that BCG protects the vaccinated elderly population.
In contrast, Japan started its universal BCG policy in 1947 and has around 100 times less deaths per million people, with 0.28 deaths. Brazil started universal vaccination in 1920 and also has an even lower mortality rate of 0.0573 deaths per million inhabitants.
Considering the results, researchers concluded that a combination of reduced morbidity and mortality makes BCG vaccination a potential new tool in the fight against COVID-19.
With inputs from IANS